|Systematic (IUPAC) name|
|Licence data||EMA:, US FDA:|
|Pregnancy cat.||D (AU) D (US)|
|Legal status||℞-only (US)|
|Half-life||1.3 to 5 hours|
|Excretion||Faecal (85%), renal (4%)|
|Mol. mass||488.01 g/mol|
|(what is this?)|
Dasatinib, previously known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral multi- BCR/Abl and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.
The drug is named after one of the inventor chemists, Jagabandhu Das, who was a member of the large discovery and development team at Bristol Myers Squibb.